SNBL Supports Domestic Drug Development in Taiwan: Expands NHPs Testing to Provide Stable and Cost-Effective Testing Plans

Source: Medgaea Life Sciences ( Healthcare+ Expo- booth no.: )

In recent years, the trend in drug development has shifted from small molecule drugs to various innovative treatment modalities such as large molecule drugs, antibodies, as well as cellular and immune therapies. Traditional animal toxicology studies may struggle to accurately assess the safety of these new treatment methods. In contrast, non-human primate (NHPs) testing has shown more aligned responses to these novel biologics. As a leading entity in Japan's longest-standing non-clinical CRO field, SNBL is committed to creating an environment that facilitates the smooth development of drug therapies.

SNBL continuously strives to optimize NHPs testing while prioritizing animal welfare to establish a stable NHPs testing environment. Leveraging its 60 years of experience in the CRO field, SNBL has developed robust safety assessment tests for new treatment methods. This enables them to effectively address the demands for NHPs studies and offer specialized, customized testing plans at a competitive pricing advantage.

For further information about the testing services and assistance provided by SNBL, please feel free to contact us at your convenience.